2-(2-甲基-1,3-噻唑-4-基)苯胺 | 305811-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-甲基-1,3-噻唑-4-基)苯胺
• 英文名称: 4-(2-aminophenyl)-2-methylthiazole
• 英文别名: 2-(2-Methyl-1,3-thiazol-4-yl)aniline
• CAS: 305811-38-5
• 化学式: C₁₀H₁₀N₂S
• mdl: MFCD09965287
• 分子量: 190.269
• InChiKey: AJFBHXXQTQAILP-UHFFFAOYSA-N

物化性质

• 沸点：
  342.9±17.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-氯甲基咪唑啉盐酸盐 、 2-(2-甲基-1,3-噻唑-4-基)苯胺 生成 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(2-methyl-1,3-thiazol-4-yl)aniline
  参考文献：
  名称：

  2-(Anilinomethyl)imidazolines as α1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series

  摘要：

  A series of 2'-heteroaryl and 2'-oxime anilinomethylimidazolines was prepared and evaluated in in vitro functional assays for cloned human alpha(1A), alpha(1B), and alpha(1D) receptor subtypes, Potent and selective alpha(1A) agonists have been identified in these series. (C) 2002 Elsevier Science Lid. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00822-8
• 作为产物：
  描述：

  2-溴-2′-硝基苯乙酮 在 platinum(IV) oxide 氢气 作用下， 以 乙醇 为溶剂， 生成 2-(2-甲基-1,3-噻唑-4-基)苯胺
  参考文献：
  名称：

  2-(Anilinomethyl)imidazolines as α1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series

  摘要：

  A series of 2'-heteroaryl and 2'-oxime anilinomethylimidazolines was prepared and evaluated in in vitro functional assays for cloned human alpha(1A), alpha(1B), and alpha(1D) receptor subtypes, Potent and selective alpha(1A) agonists have been identified in these series. (C) 2002 Elsevier Science Lid. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00822-8

文献信息

• [EN] IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS<br/>[FR] DERIVES D'IMIDAZOLINE UTILISES COMME LIGANDS DU RECEPTEUR ADRENERGIQUE ALPHA-1A
  申请人：GLAXO GROUP LTD

  公开号：WO2000066563A1

  公开（公告）日：2000-11-09

  Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Formula (i) wherein R?2, R3, R4 and R5¿ are independently H, halogen, -OH, -C¿1-3?alkyl, -C1-3alkoxy, -SC1-2alkyl, or -CF3, with the proviso that at least 2 of R?2, R3, R4 and R5¿ are H; R6 is H or -CH¿3; R?1 is -S(O)¿nR?7 where n is 1 or 2, -S(O)¿2NHR?8, -C(O)R?9, -NR14R15, -C(R17)=NOR16¿, (a) or a 5,6, or 7 membered heteroalkyl or heteroaryl group optionally substituted. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

  公开了式(I)的化合物或其药学上可接受的盐或溶剂化物。式(I)中，R?2、R3、R4和R5¿独立地为H、卤素、-OH、-C¿1-3?烷基、-C1-3烷氧基、-SC1-2烷基或-CF3，但至少有2个R?2、R3、R4和R5¿为H；R6为H或-CH¿3；R?1为-S(O)¿nR?7，其中n为1或2，-S(O)¿2NHR?8，-C(O)R?9，-NR14R15，-C(R17)=NOR16¿，(a)或可选择取代的5、6或7成员杂烷基或杂芳基基团。这些化合物在治疗α-1A介导的疾病或病况，例如尿失禁方面有用。
• AMIDE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1813606A1

  公开（公告）日：2007-08-01

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  本发明提供了一种 FAAH 抑制剂和一种用于脑血管疾病或睡眠障碍的预防或治疗剂。该预防或治疗剂包括式（I0）化合物： 其中 Z 是氧或硫；R1 是可被取代的芳基或可被取代的杂环基团；R1a 是氢原子、可被取代的烃基、羟基等。R2 是可被取代的哌啶-1,4-二基或可被取代的哌嗪-1,4-二基；R3 是通过从具有 1 至 3 个选自氮、氧和硫的杂原子的 5 元芳香杂环基团中消除两个氢原子而形成的基团，该基团可被进一步取代、-CO- 等；以及 R4 是可被取代的烃基或可被取代的杂环基；或其盐。
• IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1175406A1

  公开（公告）日：2002-01-30
• US6884801B1
  申请人：——

  公开号：US6884801B1

  公开（公告）日：2005-04-26
• 2-(Anilinomethyl)imidazolines as α1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series
  作者：Frank Navas、Michael J. Bishop、Deanna T. Garrison、Stephen J. Hodson、Jason D. Speake、Eric C. Bigham、David H. Drewry、David L. Saussy、James H. Liacos、Paul E. Irving、M.Jeffrey Gobel

  DOI：10.1016/s0960-894x(01)00822-8

  日期：2002.2

  A series of 2'-heteroaryl and 2'-oxime anilinomethylimidazolines was prepared and evaluated in in vitro functional assays for cloned human alpha(1A), alpha(1B), and alpha(1D) receptor subtypes, Potent and selective alpha(1A) agonists have been identified in these series. (C) 2002 Elsevier Science Lid. All rights reserved.